The Case for Obtaining a Diagnostic Whole-Body Scan Prior to Iodine 131 Treatment of Differentiated Thyroid Cancer

被引：15
作者：
McDougall, I. Ross [1 ]
机构：
[1] Stanford Univ, Hosp & Clin, Dept Radiol, Div Nucl Med & Mol,Imaging Program, Stanford, CA 94305 USA
来源：
THYROID | 2009年 / 19卷 / 08期
关键词：
REMNANT ABLATION; CARCINOMA; I-131; I-123; MANAGEMENT; THERAPY;
D O I：
10.1089/thy.2009.1582
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：811 / 813
页数：3
相关论文
共 17 条
  • [1] Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: A randomized clinical trial in 509 patients
    Bal, CS
    Kumar, A
    Pant, GS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (04) : 1666 - 1673
  • [2] Timing and potential role of diagnostic I-123 scintigraphy in assessing radioiodine breast uptake before ablation in postpartum women with thyroid cancer - A case series
    Brzozowska, Malgorzata
    Roach, Paul J.
    [J]. CLINICAL NUCLEAR MEDICINE, 2006, 31 (11) : 683 - 687
  • [3] The carcinogenic effects of radioiodine therapy for thyroid carcinoma
    de Vathaire, Florent
    [J]. NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (04): : 180 - 181
  • [4] Review:: 131I activity for remnant ablation in patients with differentiated thyroid cancer:: A systematic review
    Hackshaw, Allan
    Harmer, Clive
    Mallick, Ujjal
    Haq, Masud
    Franklyn, Jayne A.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (01) : 28 - 38
  • [5] 74 MBq radioiodine I-131 does not prevent uptake of therapeutic doses of I-131 (ie it does not cause stunning) in differentiated thyroid cancer
    McDougall, IR
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 1997, 18 (06) : 505 - 512
  • [6] European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
    Pacini, Furio
    Schlumberger, Martin
    Dralle, Henning
    Elisei, Rossella
    Smit, Johannes W. A.
    Wiersinga, Wilmar
    Moreno-Reyes, R.
    Van den Bruel, A.
    Zira, C.
    Feldt-Rasmussen, U.
    Godballe, C.
    Corone, C.
    Borson-Charzot, F.
    Reiners, C.
    Alevizaki, M.
    Duntas, L.
    Vlassopoulou, B.
    Esik, O.
    Mezosi, E.
    Moriarty, M. J.
    Smyth, P.
    Cohen, O.
    Krausz, Y.
    Pellegriti, G.
    Castagna, M. G.
    Marga, M.
    Bioro, T.
    Jarzab, B.
    Carrilho, F.
    de Castro, J. J.
    Limbert, E. S.
    Ioachim, D.
    Mogos, V.
    Ursu, H.
    Roumiantsev, P.
    Troshina, E.
    Hnilica, P.
    Besic, N.
    Zagar, I.
    Gomez, J. M.
    Sanchez-Franco, F.
    Berg, G.
    Tennvall, J.
    Wallin, G. K.
    Meier, C. A.
    Links, T. P.
    Ayvaz, G.
    Uysal, A. R.
    Cherenko, S.
    Larin, O.
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2006, 154 (06) : 787 - 803
  • [7] INFLUENCE OF DIAGNOSTIC RADIOIODINES ON THE UPTAKE OF ABLATIVE DOSE OF I-131
    PARK, HM
    PERKINS, OW
    EDMONDSON, JW
    SCHNUTE, RB
    MANATUNGA, A
    [J]. THYROID, 1994, 4 (01) : 49 - 54
  • [8] Detection of thyroid remnant/metastasis without stunning: An ongoing dilemma
    Park, HM
    Park, YH
    Zhou, XH
    [J]. THYROID, 1997, 7 (02) : 277 - 280
  • [9] Perros P., 2007, GUIDELINES MANAGEMEN, P18
  • [10] Second primary malignancies in thyroid cancer patients
    Rubino, C
    de Vathaire, F
    Dottorini, ME
    Hall, P
    Schvartz, C
    Couette, JE
    Dondon, MG
    Abbas, MT
    Langlois, C
    Schlumberger, M
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (09) : 1638 - 1644
12